bioAffinity (BIAF) - רווח סופי

The financial results of bioAffinity Technologies (BIAF) demonstrate profit dynamics, where -0.01 describes the current status of the metric. Growth is driven by the implementation of CyPath Lung non-invasive sputum analysis. The positive trend is supported by the scaling of tests in the US and the expansion of insurance coverage. Business efficiency is increasing through computer vision, which automates pathology detection and eliminates human error in diagnostics.

The profit trajectory of bioAffinity Technologies (BIAF) visualizes the business's market value through the lens of daily net earnings, eliminating the time lag associated with quarterly reporting. This metric reflects the cash flow from the mandatory use of Inertia diagnostic systems in clinics, where a high indicator value signals asset overvaluation, while a low value indicates a risk of investor capital stagnation.